Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up - Desrosiers - International Forum of Allergy & Rhinology - Wiley Online Library

GSK's Nucala approved to treat chronic rhinosinusitis with nasal polyps - PharmaTimes

Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps

Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study

Managing chronic rhinosinusitis with nasal polyps in elderly

Eosinophils & MOA NUCALA (mepolizumab) for CRSwNP

Biomedicines, Free Full-Text

Mepolizumab for chronic rhinosinusitis with nasal polyps - The Lancet Respiratory Medicine

Frontiers Pathogenesis and treatment of chronic rhinosinusitis from the perspective of sinonasal epithelial dysfunction

FDA approves GSK's Nucala for use in adults with chronic rhinosinusitis with nasal polyps - PharmaLive

JCM, Free Full-Text

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine